Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
OMED's Cash to Debt is ranked higher than
74% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. OMED: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OMED' s 10-Year Cash to Debt Range
Min: 326.31  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.29
OMED's Equity to Asset is ranked lower than
86% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OMED: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
OMED' s 10-Year Equity to Asset Range
Min: -2.45  Med: 0.32 Max: 0.7
Current: 0.29
-2.45
0.7
Interest Coverage No Debt
OMED's Interest Coverage is ranked lower than
57% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OMED' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 1.21
M-Score: 265.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -118.56
OMED's Operating margin (%) is ranked lower than
56% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. OMED: -118.56 )
Ranked among companies with meaningful Operating margin (%) only.
OMED' s 10-Year Operating margin (%) Range
Min: -161.06  Med: -90.63 Max: -48.52
Current: -118.56
-161.06
-48.52
Net-margin (%) -117.20
OMED's Net-margin (%) is ranked lower than
57% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. OMED: -117.20 )
Ranked among companies with meaningful Net-margin (%) only.
OMED' s 10-Year Net-margin (%) Range
Min: -152.47  Med: -90.09 Max: -47.87
Current: -117.2
-152.47
-47.87
ROE (%) -59.02
OMED's ROE (%) is ranked lower than
68% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. OMED: -59.02 )
Ranked among companies with meaningful ROE (%) only.
OMED' s 10-Year ROE (%) Range
Min: -51.43  Med: -51.43 Max: -51.43
Current: -59.02
ROA (%) -19.02
OMED's ROA (%) is ranked higher than
56% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. OMED: -19.02 )
Ranked among companies with meaningful ROA (%) only.
OMED' s 10-Year ROA (%) Range
Min: -28.05  Med: -20.49 Max: -12.61
Current: -19.02
-28.05
-12.61
ROC (Joel Greenblatt) (%) -1012.26
OMED's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. OMED: -1012.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1038.97  Med: -480.24 Max: -382.73
Current: -1012.26
-1038.97
-382.73
» OMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

OMED Guru Trades in Q2 2014

Jim Simons 59,200 sh (New)
PRIMECAP Management 266,400 sh (-21.81%)
» More
Q3 2014

OMED Guru Trades in Q3 2014

PRIMECAP Management 218,400 sh (-18.02%)
Jim Simons 40,110 sh (-32.25%)
» More
Q4 2014

OMED Guru Trades in Q4 2014

PRIMECAP Management 218,400 sh (unchged)
Jim Simons 20,675 sh (-48.45%)
» More
Q1 2015

OMED Guru Trades in Q1 2015

Jim Simons Sold Out
PRIMECAP Management 206,293 sh (-5.54%)
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.33
OMED's P/B is ranked lower than
74% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. OMED: 10.33 )
Ranked among companies with meaningful P/B only.
OMED' s 10-Year P/B Range
Min: 3.52  Med: 7.42 Max: 12.85
Current: 10.33
3.52
12.85
P/S 15.73
OMED's P/S is ranked lower than
55% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. OMED: 15.73 )
Ranked among companies with meaningful P/S only.
OMED' s 10-Year P/S Range
Min: 1.03  Med: 12.15 Max: 20.34
Current: 15.73
1.03
20.34
Current Ratio 6.43
OMED's Current Ratio is ranked higher than
60% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. OMED: 6.43 )
Ranked among companies with meaningful Current Ratio only.
OMED' s 10-Year Current Ratio Range
Min: 1.89  Med: 5.19 Max: 6.43
Current: 6.43
1.89
6.43
Quick Ratio 6.43
OMED's Quick Ratio is ranked higher than
61% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. OMED: 6.43 )
Ranked among companies with meaningful Quick Ratio only.
OMED' s 10-Year Quick Ratio Range
Min: 1.89  Med: 5.19 Max: 6.43
Current: 6.43
1.89
6.43
Days Sales Outstanding 60.09
OMED's Days Sales Outstanding is ranked higher than
51% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. OMED: 60.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMED' s 10-Year Days Sales Outstanding Range
Min: 0.22  Med: 59.49 Max: 65.72
Current: 60.09
0.22
65.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.84
OMED's Price/Net Cash is ranked lower than
65% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. OMED: 13.84 )
Ranked among companies with meaningful Price/Net Cash only.
OMED' s 10-Year Price/Net Cash Range
Min: 5.05  Med: 9.32 Max: 15.62
Current: 13.84
5.05
15.62
Price/Net Current Asset Value 11.77
OMED's Price/Net Current Asset Value is ranked lower than
59% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. OMED: 11.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OMED' s 10-Year Price/Net Current Asset Value Range
Min: 4.42  Med: 8.96 Max: 13.29
Current: 11.77
4.42
13.29
Price/Tangible Book 10.48
OMED's Price/Tangible Book is ranked lower than
66% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. OMED: 10.48 )
Ranked among companies with meaningful Price/Tangible Book only.
OMED' s 10-Year Price/Tangible Book Range
Min: 4.22  Med: 7.52 Max: 11.83
Current: 10.48
4.22
11.83
Price/Median PS Value 1.30
OMED's Price/Median PS Value is ranked higher than
51% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. OMED: 1.30 )
Ranked among companies with meaningful Price/Median PS Value only.
OMED' s 10-Year Price/Median PS Value Range
Min: 0.1  Med: 0.92 Max: 1.48
Current: 1.3
0.1
1.48
Earnings Yield (Greenblatt) (%) -11.05
OMED's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. OMED: -11.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMED' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -13.33  Med: 0.00 Max: 0
Current: -11.05
-13.33
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:O0M.Germany,
OncoMed Pharmaceuticals Inc was originally incorporated in July 19, 2004 in Delaware. The Company is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs. CSCs, also known as tumor-initiating cells, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs exhibit certain properties which include the capacity to divide and give rise to new CSCs via self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. It faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The Company has a total of over 400 patents and pending patent applications in our patent portfolio. The Company's product candidates are subject to regulation by the FDA as biologics.
» More Articles for OMED

Headlines

Articles On GuruFocus.com
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 

More From Other Websites
5 Stocks Ready for Breakouts Jul 31 2015
OncoMed Initiates Phase 1 Clinical Trial for Anti-RSPO3 Antibody Jul 28 2015
OncoMed Initiates Phase 1 Clinical Trial for Anti-RSPO3 Antibody Jul 28 2015
OncoMed to Present at the Cantor Fitzgerald Inaugural Healthcare Conference Jul 06 2015
OncoMed to Present at the Cantor Fitzgerald Inaugural Healthcare Conference Jul 06 2015
ONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 29 2015
OncoMed Pharmaceuticals Appoints Rick Winningham to Board of Directors Jun 29 2015
OncoMed Pharmaceuticals Appoints Rick Winningham to Board of Directors Jun 29 2015
ONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 25 2015
Grupo Nutresa SA Earnings Call scheduled for 7:00 am ET today Jun 02 2015
OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual... Jun 01 2015
OncoMed Presents Phase 1b Clinical Trial Data for Tarextumab in Small Cell Lung Cancer at the 2015... Jun 01 2015
OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual... Jun 01 2015
OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual... Jun 01 2015
OncoMed Presents Phase 1b Clinical Trial Data for Tarextumab in Small Cell Lung Cancer at the 2015... Jun 01 2015
OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual... Jun 01 2015
OncoMed to Present at Upcoming Investment Conferences May 28 2015
OncoMed Pharmaceuticals to Review Key ASCO Data for Demcizumab and Tarextumab During Conference Call... May 28 2015
OncoMed to Present at Upcoming Investment Conferences May 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK